Back

Solstice Oncology raises $225 million to advance colon cancer antibody

Verifying
  • Solstice Oncology raised Series A financing to develop porustobart for colon cancer.
  • $225 million will support a Phase II Keytruda combination trial.
  • Enrollment is scheduled for the fourth quarter of 2026, with data expected in 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Solstice Oncology raises $225 million to advance colon cancer antibody - CoinPost Terminal